Reduced levels of clotting factor XI cause hemophilia C, also called factor XI deficiency. It’s a rare form of hemophilia involving bleeding following trauma or surgery, including dental procedures.

Hemophilia is a rare, inherited disease that causes blood to not clot as it should and can cause spontaneous bleeding. Learn how this affects your prognosis.

An estimated 7700 people in England have haemophilia A, with around 1900 classified as severe cases where their factor VIII activity level is less than 1%. Current treatments involve factor VIII ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

The EMA's human medicines advisory committee has recommended that BioMarin Pharmaceutical's haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to launch.

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the ...